-0.19Basic and diluted earnings/(loss) per share Weighted average number of sharesof common stock outstanding - Basic55,382,32955,023,07055,235,19854,881,874- Diluted55,882,83755,023,07055,684,69154,881,874
SINOVAC BIOTECH LTD.Incorporated in Antigua and BarbudaConsolidated Statements of Cash FlowsThree and Nine Months Ended September 30, 2013 and 2012(Unaudited)(Expressed in U.S. Dollars)Three Months ended September 30Nine Months ended September 302013201220132012Cash flows used in operating activities Net income(loss) for the period
-13,735,604 Adjustments to reconcile net income (loss) to net cash used in operating activities: - deferred income taxes76,6725,95861,88972,287 -Impairment of equipment and loss(gain) on disposal-83,468-2,3275,928 - unrealized foreign exchange gain----43,880 - stock-based compensation71,685134,138209,378388,104- inventory provision2,640776,838770,4511,365,628- provision for doubtful accounts171,72897,0671,057,52097,067 - depreciation of property, plant and equipment, and
amortization of licenses and renovation costs1,649,6391,124,9465,135,1793,673,159 - research and development expenditures qualified for government grant---78,980- deferred government grant recognized in income--68,712-467,570- accretion expenses19,00748,56071,380185,349Changes in: - accounts receivable-7,165,298-6,631,251-15,452,983-7,302,483 - inventories734,5451,287,997-5,922,498-4,140,923- income tax payable--375-3,124,852 - prepaid expenses and deposits-428,282560,264-172,7391,048,642- deferred revenue-3,482,7351,456,127-4,711,3781,356,605
|SOURCE Sinovac Biotech Ltd.|
Copyright©2012 PR Newswire.
All rights reserved